<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01728051</url>
  </required_header>
  <id_info>
    <org_study_id>MEL 2009-01</org_study_id>
    <nct_id>NCT01728051</nct_id>
  </id_info>
  <brief_title>Expanded Access Study of Melphalan With Delcath CS-PHP System in Patients With Ocular/Cutaneous Melanoma Mets to Liver</brief_title>
  <official_title>An Open Label, Expanded Access Study of Melphalan Chemosaturation With the Delcath System in Patients With Ocular and Cutaneous Melanoma Metastatic to the Liver</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Delcath Systems Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Delcath Systems Inc.</source>
  <brief_summary>
    <textblock>
      The safety and efficacy of CS-PHP-melphalan has been evaluated in a phase 3 trial conducted&#xD;
      in the same patient population as well as using the same melphalan dosing as proposed in this&#xD;
      study. This expanded access protocol will provide an experimental alternative treatment&#xD;
      option for both physicians and patients until the Delcath CS-PHP System receives marketing&#xD;
      approval.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>No longer available</overall_status>
  <study_type>Expanded Access</study_type>
  <condition>Metastatic Liver Cancer</condition>
  <condition>Ocular Melanoma</condition>
  <condition>Cutaneous Melanoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Percutaneous Hepatic Perfusion</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically proven ocular/cutaneous melanoma with liver-dominant unresectable&#xD;
             metastatic disease, defined as limited extra-hepatic disease and hepatic involvement&#xD;
             which would, in the Investigator's opinion, result in morbidity and eventual&#xD;
             mortality. Limited extra-hepatic disease considered acceptable includes:&#xD;
&#xD;
               -  up to 4 pulmonary nodules, each &lt;1cm in diameter&#xD;
&#xD;
               -  retroperitoneal lymph nodes &lt;1cm in diameter&#xD;
&#xD;
               -  resectable skin or subcutaneous metastases&#xD;
&#xD;
               -  asymptomatic bone metastases that have been, or can be, palliated with external&#xD;
                  beam radiation therapy&#xD;
&#xD;
               -  a solitary metastasis to any site that can be resected with limited morbidity or&#xD;
                  controlled with radiation&#xD;
&#xD;
          2. ≥1 measurable hepatic lesion per RECIST 1.1&#xD;
&#xD;
          3. Vasculature compatible with insertion of CS-PHP catheters, per baseline abdominal MRA&#xD;
&#xD;
          4. ECOG PS 0-2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Chemotherapy, radiotherapy, or biologic therapy for the malignancy ≤1 month prior to&#xD;
             1st CS-PHP-melphalan infusion&#xD;
&#xD;
          2. Extensive prior radiotherapy, defined as treatment to ≥50% of marrow-containing bones&#xD;
&#xD;
          3. Immunosuppressive drugs such as cyclosporine, tacrolimus, azathioprine, or long-term&#xD;
             oral glucocorticoids taken currently or ≤3 mths prior to 1st CS-PHP-melphalan infusion&#xD;
&#xD;
          4. Received an investigational product ≤30 days prior to the 1st CS-PHP-melphalan&#xD;
             infusion&#xD;
&#xD;
          5. History of orthotopic liver transplantation, untreated gastrinoma (i.e. gastric acid&#xD;
             hypersecretion) or prior Whipple procedure&#xD;
&#xD;
          6. Not recovered from side effects of prior therapy to ≤ Grade 1 NCI CTCAE 4.03&#xD;
&#xD;
          7. Child's B or C cirrhosis, or clinical evidence of portal hypertension&#xD;
&#xD;
          8. Patients with &gt;50% of liver replaced by tumor, histologic evidence of hepatic&#xD;
             dysfunction seen by laparoscopic liver biopsy&#xD;
&#xD;
          9. History or evidence of clinically significant cardiac disease such as symptomatic&#xD;
             arrhythmia, angina/ischemia, coronary artery bypass graft surgery or percutaneous&#xD;
             transluminal coronary angioplasty, uncontrolled atrial fibrillation, CHF with a left&#xD;
             ventricular ejection fraction &lt;40%, uncontrolled hypertension (SBP &gt;190 mmHg or DBP&#xD;
             &gt;100 mmHg), HR outside normal range of 50-100 bpm for women and 45-100 bpm for men&#xD;
&#xD;
         10. History/evidence of clinically significant pulmonary or cardiac disease incompatible&#xD;
             with fitness to undergo general anesthesia&#xD;
&#xD;
         11. Uncontrolled diabetes mellitus or hypo/hyperthyroidism&#xD;
&#xD;
         12. Active uncontrolled infection&#xD;
&#xD;
         13. History of bleeding disorders or known unresolved venous shunting&#xD;
&#xD;
         14. Requirement for ongoing chronic anticoagulation&#xD;
&#xD;
         15. Evidence of intracranial abnormalities resulting in risk for bleeding with&#xD;
             anticoagulation&#xD;
&#xD;
         16. History of alcohol or drug abuse ≤6 mths&#xD;
&#xD;
         17. Other malignancy within 3 yrs before enrollment with the exception of curatively&#xD;
             treated basal or squamous cell carcinoma of the skin, or curatively treated cervical,&#xD;
             breast carcinoma in situ or prostate cancer&#xD;
&#xD;
         18. History of hypersensitivity to: melphalan or its components; iodine contrast that&#xD;
             cannot be controlled by premedication with antihistamines and steroids; latex&#xD;
&#xD;
         19. Known hypersensitivity to heparin in the presence of heparin-induced thrombocytopenia&#xD;
             antibodies&#xD;
&#xD;
         20. Inadequate hematological or renal function as indicated by any of the following:&#xD;
&#xD;
               -  Platelets &lt;100,000/mm3&#xD;
&#xD;
               -  Hb ≤10 g/dL&#xD;
&#xD;
               -  Neutrophils &lt;2,000/mm3&#xD;
&#xD;
               -  S Creat &gt;1.5 mg/dL or measured creatinine clearance &lt;60 mL/min/1.73 m2&#xD;
&#xD;
         21. Inadequate liver function as indicated by any of the following:&#xD;
&#xD;
               -  Tbili ≥3.0 mg/dL&#xD;
&#xD;
               -  INR &gt;1.5&#xD;
&#xD;
               -  AST/ALT &gt;5xULN&#xD;
&#xD;
         22. Pregnant or nursing&#xD;
&#xD;
         23. Positive pregnancy test in subjects of childbearing potential ≤7 days prior to first&#xD;
             CS-PHP-melphalan infusion&#xD;
&#xD;
         24. Women who are pre-menopausal (i.e. have had a menstrual period ≤12 months) who are&#xD;
             unwilling or unable to undergo hormonal suppression to avoid menstruation during&#xD;
             treatment&#xD;
&#xD;
         25. Sexually active females of childbearing potential and sexually active males with&#xD;
             partners of reproductive potential unwilling or unable to use contraception from&#xD;
             screening until at least 30 days after last administration of CS-PHP-melphalan&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Charles W Nutting, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sky Ridge Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jonathan Zager, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>H. Lee Moffitt Cancer Center and Research Institue at University of Southern Florida</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark Faries, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>John Wayne Cancer Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James F Pingpank, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Univeristy of Pittsburg Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eric D Whitman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Carol G. Simon Cancer Center at Morristown Memorial Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>H. Richard Alexander, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland, College Park</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>John Wayne Cancer Institute at Saint John's Health Center</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sky Ridge Medical Center</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute at University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612-9497</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carol G. Simon Cancer Center at Morristown Memorial Hospital</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07962-1956</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburg Cancer Institute</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.delcath.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>October 2013</verification_date>
  <study_first_submitted>November 13, 2012</study_first_submitted>
  <study_first_submitted_qc>November 13, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2012</study_first_posted>
  <last_update_submitted>October 22, 2013</last_update_submitted>
  <last_update_submitted_qc>October 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 23, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Skin Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melphalan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

